NCT06549309 Trial of JMKX003801 in Healthy Participants
| NCT ID | NCT06549309 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Jemincare |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-08-17 |
| Primary Completion | 2025-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 70 participants in total. It began in 2024-08-17 with a primary completion date of 2025-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003801 Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Dose in Chinese Healthy Adult Participants
Eligibility Criteria
Inclusion Criteria: * The subjects have a thorough understanding of the study content, process, and potential adverse effects, and are willing to complete the study according to the requirements of the experimental protocol; * Healthy adult males and/or females, 18 to 45 years of age; * Body mass index (BMI) ≥ 19 and ≤ 28.0 (kg/m2) ,weight ≥45kg (female) or ≥50kg (male) . Exclusion Criteria: * Had or currently have serious clinical diseases related to circulatory system, respiratory system, digestive system, nervous system, endocrine system, blood lymphatic system, genitourinary system or psychiatry, or any other diseases judged by investigators that will be interference to the results of this study; * Use of any over-the-counter (OTC) medication, prescription medicine, Chinese herbal medicine , within 2 weeks prior to the time of informed consent signed; * Pregnant or lactating women; * Other conditions unsuitable for the trial judged by the investigators.
Contact & Investigator
Jing Zhang
PRINCIPAL INVESTIGATOR
Huashan Hospital
Frequently Asked Questions
Who can join the NCT06549309 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06549309 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06549309 currently recruiting?
Yes, NCT06549309 is actively recruiting participants. Contact the research team at jihongzhang@jemincare.com for enrollment information.
Where is the NCT06549309 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06549309 clinical trial?
NCT06549309 is sponsored by Jemincare. The principal investigator is Jing Zhang at Huashan Hospital. The trial plans to enroll 70 participants.